Tag: hVIVO

January 2, 2024 Off

£6.3m HRV contract signed with biotechnology client

hVIVO has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV – common cold virus) Human Challenge Study Model.

February 9, 2017 Off

PrEP Biopharm’s asthma study misses goal, but gives useful insights

By Dino Mustafić

PrEP Biopharm’s study of its drug, earlier confirmed helpful for influenza and human rhinoviruse (HRV), has been undertaken to test its efficacy of the people with asthma, and check for different dosage, showed varying results.